THPO

Thrombopoietin · P40225 · THPO on Sugi Atlas →

243,633 patent compounds predicted against THPO, 187,137 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Chlorpromazine (SCHEMBL8321)	1.00	5/20
Prochlorperazine (SCHEMBL18429)	1.00	4/20
Fluphenazine (SCHEMBL19221)	1.00	3/20
Trifluoperazine (SCHEMBL24866)	1.00	3/20
Z-Flupentixol (SCHEMBL34200)	1.00	3/20
Carbidopa Anhydrous (SCHEMBL35084)	1.00	3/20
Trimipramine (SCHEMBL35144)	1.00	3/20
Methyldopa (SCHEMBL34003)	0.65	3/20
Carbinoxamine (SCHEMBL5070)	0.62	3/20
Amiloride (SCHEMBL27563)	0.60	3/20
Levodopa (SCHEMBL22655)	0.58	3/20
Levodopa (SCHEMBL24360)	0.58	3/20
SCHEMBL34002	0.53	3/20
Amiloride (SCHEMBL27562)	0.52	3/20
SCHEMBL6254	0.44	3/20
Embramine (SCHEMBL28365)	0.40	3/20
Dexchlorpheniramine (SCHEMBL3538)	1.00	2/20
Vinblastine (SCHEMBL3628)	1.00	2/20
Vinblastine (SCHEMBL3629)	1.00	2/20
Vincristine (SCHEMBL3709)	1.00	2/20

Clinical trials — most relevant to THPO by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Erythropoietin and Platelet Activation Markers	PHASE4	COMPLETED
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	PHASE3	UNKNOWN
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial	PHASE3	UNKNOWN
An Investigation of rhTPO With Different Frequencies in the Management of ITP	PHASE3	COMPLETED
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA	PHASE3	UNKNOWN
A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP	PHASE2/PHASE3	COMPLETED
Prospective Study of Patients With Thrombocytopenia Following HSCT	PHASE3	COMPLETED
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)	PHASE2	COMPLETED
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)	PHASE2	RECRUITING
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer	PHASE2	NOT_YET_RECRUITING
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma	PHASE2	NOT_YET_RECRUITING
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	PHASE2	RECRUITING
The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients	PHASE2	COMPLETED
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae	PHASE2	NOT_YET_RECRUITING
Eltrombopag for Moderate Aplastic Anemia	PHASE2	COMPLETED
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer	PHASE2	NOT_YET_RECRUITING
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)	PHASE1/PHASE2	COMPLETED
IVIg Plus Low Dose rhTPO for ITP in Pregnancy	PHASE2	UNKNOWN
Extended Dosing With Eltrombopag for Severe Aplastic Anemia	PHASE2	COMPLETED
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease	PHASE1	UNKNOWN
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis	PHASE1	RECRUITING
Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers	PHASE1	COMPLETED
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)	PHASE1	RECRUITING
Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital	nan	UNKNOWN
A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient	nan	COMPLETED
rhTPO Dose Escalation vs Eltrombopag Switch in ITP	nan	NOT_YET_RECRUITING
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study	nan	UNKNOWN
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation	nan	UNKNOWN
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a THPO binder may also engage these)

Protein	Name	Similarity
P42705	—	1.000	P42705 →
P49745	—	0.997	P49745 →
P40226	—	0.993	P40226 →
P09603	—	0.983	P09603 →
Q8JZQ0	—	0.982	Q8JZQ0 →
Q2TB54	—	0.978	Q2TB54 →
B0BN44	—	0.977	B0BN44 →
P07141	—	0.976	P07141 →
D4A9R4	—	0.976	D4A9R4 →
Q6P1B3	—	0.976	Q6P1B3 →
Q6PE13	—	0.976	Q6PE13 →
Q5BK39	—	0.976	Q5BK39 →
Q91V98	—	0.975	Q91V98 →
Q8IXW0	—	0.975	Q8IXW0 →
Q5U2P6	—	0.975	Q5U2P6 →
O08574	—	0.975	O08574 →
P49157	—	0.975	P49157 →
Q5M871	—	0.975	Q5M871 →
Q8BHE4	—	0.974	Q8BHE4 →
A6QLF8	—	0.974	A6QLF8 →
P53346	—	0.974	P53346 →
Q9H2A7	—	0.974	Q9H2A7 →
P07321	—	0.973	P07321 →
P33708	—	0.973	P33708 →
Q8CII8	—	0.973	Q8CII8 →
Q8BG26	—	0.973	Q8BG26 →
P01588	—	0.973	P01588 →
Q5F267	—	0.973	Q5F267 →
Q8N1P7	—	0.973	Q8N1P7 →
Q96PX9	—	0.973	Q96PX9 →